anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypertensive intracerebral hemorrhage (HICH) is one of the main causes of death and disability in Chinese people. Surgical treatment can reduce the mortality rate of patients with HICH, but cannot improve functional prognosis. Therefore, promoting the neurological function recovery of surviving patients has become the focus of treatment for HICH. The corticospinal tract (CST) is the main descending fiber bundle that maintains motor function, and its integrity determines the degree of motor function recovery. Therefore, reducing CST injury is expected to improve motor dysfunction in patients with supratentorial deep HICH. Standardizing the indications, surgical strategies, and operational procedures for minimally invasive surgical treatment via the parafascicular approach can achieve maximum hematoma clearance and minimal white fiber bundle damage, which is beneficial for promoting the recovery of white matter fibers and improving neurological function prognosis. The Chinese Congress of Neurological Surgeons of Chinese Medical Doctor Association, the Neurosurgery Branch of the Chinese Medical Association, the Intracerebral Hemorrhage Minimally Invasive Surgical Treatment Branch of the Chinese Stroke Association, and the Stroke Branch of the Chongqing Medical Association organized relevant domestic experts to systematically query and evaluate existing relevant research evidence, refer to relevant international consensus and guidelines, and combine national conditions and domestic needs. A total of 31 recommendations were formed for preoperative examination, surgical indications, intraoperative positioning, surgical methods, hemostasis techniques, and perioperative management for surgical treatment of HICH based on white matter fiber protection, hoping to provide important reference for the surgical treatment of HICH.
The invention provides a levoulifloxacin mesylate crystal. The Cu-Kalpha radiated X-ray powder diffraction pattern of the crystal has the following 2theta angel expressed peaks: 5.4-5.8 degrees, 18-18.4 degrees and 25.8-26.2 degrees. The invention also provides a preparation method of the crystal, a medical composition containing the crystal, as well as medical application of the crystal and the medical composition. The crystal provided in the invention has good reproducibility, as well as simple and rapid preparation method. Experiments prove that the crystal of the invention is better than existing crystals in terms of solubility, stability, hygroscopicity and treatment effects in vivo. The crystal in the invention can also be prepared into a plurality preparation forms for use and has good clinical application potential.
Abstract I am working on the project of the new White bread, medically enhanced bread with medicine(pharmaceutical benefits healthy bread)We would like to create an extract of honey, ginger and garlic bread to enhance the health of white bread This seems to produce the best results for health whilst not changing the taste ,smell, structure and existing, ingredients of white bread. Delicious is a new innovation. First of all there is a small portions of honey, ginger and garlic, which is effective for health benefits. This idea can compare to homeopathy, when the small additions can have a large effect on the hole situation. Therefore We need a strong, concentrated extract of honey, ginger and garlic resulting in a small quantity of good quality, extract on the latest line. The new white bread containing the ginger, honey and garlic. Extract can help with weight control, effect of aging and can boost energy level. Second We are working on the project ginger ,honey ,garlic and lupin This medical bread is the first time on the market. It gives all benefits of a new ginger,honey,garlic and lupin bread.
This study aimed to determine the effects of chlorogenic acid (CGA) on the growth performance, intestinal health, immune response, and mitochondrial DNA (mtDNA)-cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway in broilers under necrotic enteritis (NE) challenge. The 180 one-day-old male Cobb 500 broilers with similar body weight of 44.59 ± 1.39 g were randomly allocated into 3 groups. The groups were control diet (Control group), control diet + NE challenge (NE group), and control diet + 500 mg/kg CGA + NE challenge (NE + CGA group), with 6 replicates per treatment. All broilers except the Control group were given sporulated coccidian oocysts (d 14) and Clostridium perfringens (d 19-21) by oral gavage. Our findings showed that CGA improved the growth performance and intestinal morphology in broilers under NE challenge. CGA supplementation elevated the barrier function in broilers under NE challenge, which reflected in the decreased serum concentrations of D-lactate and diamine oxidase, and upregulated jejunal protein expression of occludin. CGA supplementation also improved the immune function, which reflected in the increased concentrations and gene expressions of anti-inflammatory factors, and decreased concentrations and gene expressions of proinflammatory factors. CGA supplementation further enhanced intestinal cell proliferation and differentiation, which manifested in the increased number of goblet cells and positive cells of proliferating cell nuclear antigen on d 28 and 42. Furthermore, CGA supplementation decreased the mtDNA (d 42) and mitochondrial reactive oxygen species levels (d 28 and 42), and increased the mitochondrial membrane potential (d 42) and mitochondrial complex I (d 28 and 42) or III (d 28) activity. Broilers challenged with NE had upregulated jejunal protein expressions of cGAS, phospho-TANK-binding kinase 1, and phospho-interferon regulatory factor 7 compared with the Control group, which were downregulated after CGA supplementation. In conclusion, dietary supplementation CGA could protect against intestinal inflammation and injury by reducing the leakage of mtDNA and inactivating the cGAS-STING signaling pathway in broilers under NE challenge.
The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
Abacavir: Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an in vitro cytogenetic study in human lymphocytes. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse lymphoma assay. Abacavir was clastogenic in males and not clastogenic in females in an in vivo mouse bone marrow micronucleus assay. Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.

Lamivudine: Lamivudine was mutagenic in an L5178Y mouse lymphoma assay and clastogenic in a cytogenetic assay using cultured human lymphocytes. Lamivudine was not mutagenic in a microbial mutagenicity assay, in an in vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.
Initially 12 eligible patients will be enrolled for upfront ICI. At 12 week assessment if \>6 patients have response (NO radiation for recurrence/progression), an additional 6 patients will be enrolled for upfront ICI. All patients will be assessed at 12 weeks from the start of ICI. If 6 or fewer patients have response (NO radiation for progression/recurrence), no more patients will be recruited to this domain.
The vaginal microbiome is an immune defense against reproductive diseases and can serve as an important biomarker for cervical cancer. However, the intrinsic relationship between the recurrence and the vaginal microbiome in patients with cervical cancer before and after concurrent chemoradiotherapy is poorly understood. Here, we analyzed 125 vaginal microbial profiles from a patient cohort of stage IB-IVB cervical cancer using 16S metagenomic sequencing and deciphered the microbial composition and functional characteristics of the recurrent and non-recurrent both before and after chemoradiotherapy. We demonstrated that the abundance of beneficial bacteria and stability of the microbial community in the vagina decreased in the recurrence group, implying the unique characteristics of the vaginal microbiome for recurrent cervical cancer. Moreover, using machine learning, we identified Lactobacillus iners as the most important biomarker, combined with age and other biomarkers (such as Ndongobacter massiliensis, Corynebacterium pyruviciproducens ATCC BAA-1742, and Prevotella buccalis), and could predict cancer recurrence phenotype before chemoradiotherapy. This study prospectively employed rigorous bioinformatics analysis and highlights the critical role of vaginal microbiota in post-treatment cervical cancer recurrence, identifying promising biomarkers with prognostic significance in the context of concurrent chemoradiotherapy for cervical cancer. The role of L. iners in determining chemoradiation resistance in cervical cancer warrants further detailed investigation. Our results expand our understanding of cervical cancer recurrence and help develop better strategies for prognosis prediction and personalized therapy.
Eligible participants from Part A and Part B will enter Part C. Part A participants will get Dose 1. Part B participants who received Dose 1 or Dose 2 will remain on Dose 1 or Dose 2. Part B placebo participants will be randomized 1:1 to receive Dose 1 or Dose 2.
The Aurora-A kinase (AurkA) and its major regulator TPX2 (Targeting Protein for Xklp2) are key mitotic players frequently co-overexpressed in human cancers, and the link between deregulation of the AurkA/TPX2 complex and tumourigenesis is actively investigated. Chromosomal instability, one of the hallmarks of cancer related to the development of intra-tumour heterogeneity, metastasis and chemo-resistance, has been frequently associated with TPX2-overexpressing tumours. In this study we aimed to investigate the actual contribution to chromosomal instability of deregulating the AurkA/TPX2 complex, by overexpressing it in nontransformed hTERT RPE-1 cells. Our results show that overexpression of both AurkA and TPX2 results in increased AurkA activation and severe mitotic defects, compared to AurkA overexpression alone. We also show that AurkA/TPX2 co-overexpression yields increased aneuploidy in daughter cells and the generation of micronucleated cells. Interestingly, the p53/p21 axis response is impaired in AurkA/TPX2 overexpressing cells subjected to different stimuli; consistently, cells acquire increased ability to proliferate after independent induction of mitotic errors, i.e. following nocodazole treatment. Based on our observation that increased levels of the AurkA/TPX2 complex affect chromosome segregation fidelity and interfere with the activation of a pivotal surveillance mechanism in response to altered cell division, we propose that co-overexpression of AurkA and TPX2 per se represents a condition promoting the generation of a genetically unstable context in nontransformed human cells.
The present invention belongs to the field of biochemical separation and purifying technology. One new kind of hematogenesis factor of molecular weight 50000-52000, isoelectric point 3.8-4.2 and erythropoiesis promoting function is found from blood plasma and named Erythrocyte proliferating factor (EPF). EPF is initially determined to be one number in DBP. EPF is prepared with the alcohol precipitate of blood plasma after separating out albumin and globulin, and through dissolving, centrifugation, ultrafiltering, DEAE cellulose chromatography and gel filtering; and it may be prepared into freeze dried preparation. EPF and EPO may be used cooperatively to produce obvious synergistic effect of promoting erythropoiesis; and EPF will not increase blood viscosity and has no obvious toxic side effect. EPF is one natural, humanized, safe and effective erythropoiesis promoting factor.
Total participation for each patient is approximately 16-17 weeks, which may include up to a 2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up. During the run-in period patients taking statins, statin combination or Zetia will undergo a 'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their same diet prior to entering the study). They will be asked to defer initiating any weight loss diets or meaningful changes in their activity level until after they have completed the study. Once randomized into the double blind study, patients will visit the clinic every two weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the double-blind study medication will be discontinued. Patients will attend a follow up visit two weeks after their final dose for safety evaluation.
The method is immunochemical and is used for the production of antigen from immune complexes recirculating in the blood, as well as for the production of monoclonal antibodies by hybridome techniques. By it, serum from leucosis cows is fractionated by ion-echange chromatography on DEAE-cellulose at ionic strength of 0.02 and pH 7.6-8.0. Immune complexes are bound on the cellulose, and the serum immunoglobuline are eliminated by the eluate. The bound complexes are freed from the ion-exchange cellulose by eluation by 2.5-3.0 ml 2 M sodium chloride per ml initial serum. The ionic strength of the eluate is reduced to 0.15 by dialysis or desalination gelfiltration. In the protein solution produced the immune complexes are selectively settled at 3.5 polyethyleneglycol concentration in the mixture with mol. wt. 6000. The complexes settled and separated are washed once in 3.5% polyethyleneglycol and twice in acetone, are dispersed in 0.01 M Thris-hydrochloric acid buffer, pH 8.0 containing 0.1 - 0.02% sodium dodecylsulphate and 0.8 -1.0% 2-mercaptoethanol and are placed in water bath at 60°C for 30-40 min. The slightly opalescent solution containing the antigen is dialysed 24 hrs against PBS, pH 7.4 and is stored at -20°C.
Sustained release devices have an insoluble polymer and glycerol ester matrix containing an active substance. Preferred devices are solid implants for subcutaneous administration, containing one or more anabolic substances incorporated in the matrix. The implants give sustained release of the anabolic substance especially in farm animals. The anabolic substance is e.g. estradiol, testosterone, progesterone, nandrolone, trembolone etc. The insoluble polymer may be polypropylene, polyethylene, pvc, polystyrene etc, and the ester can be glycerol palmitostearate, stearate or behenate.
Subjects allocated to the control group are hemodynamically managed as per anesthesiologist preference. Typically, isolated hypotension (20% decrease in mean arterial pressure below baseline or \< 60 mmHg) is treated by single or consecutive boluses of norepinephrine 5 or 10 μg. If hypotension persists, repeat boluses of ephedrine 4 mg will be administered until mean arterial pressure is above 60 mmHg. If hypotension is accompanied by signs of hypovolemia (urine output \< 0.5 ml·kg-1·hr-1 and/or an increase in heart rate \> 20% above baseline), crystalloid or colloid fluids will be given until urine output and/or heart rate are normalized. If hypotension persists despite volume challenge, norepinephrine will be used.
Spermidine has significant effects of cardioprotection and neuroprotection, and can improve a mechanical elastic function of cardiomyocytes by an autophagy mechanism to delay aging. Lycium ruthenicum Murr. is the only plant resource that has been recorded as a natural heart drug among spermidine-rich foods. A low-concentration formic acid aqueous solution serves as extraction solvents in a preparation process, a solution of ethanol: water: formic acid serves as eluents, and macroporous adsorption resins serve as separation materials. Solvents used in the present disclosure are safe and non-toxic, low in price and recyclable. A production process is safe and simple, free of pollution to environment, easy to control, and suitable for large-scale industrial production.
PURPOSE:To obtain a gelatin film composition capable of preventing the insolubilization of gelatin with time caused by caramel while keeping the characteristic color and light-shielding effect of caramel, by adding caramel having a specific light-transmittance and an amino acid to gelatin. CONSTITUTION:The objective gelatin film composition contains (A) a caramel having a light-transmittance of 15-60% at 310nm wavelength as 0.01wt.% aqueous solution and (B) an amino acid (e.g. aspartic acid, glycine and lysine) at a weight ratio of 1:0.01-1. The insolubilizing action of caramel on gelatin can be suppressed by the addition of an amino acid together with caramel. The composition is suitable as a composition for soft capsule to hold a substance required to be kept from light, e.g. tocopherols, vitamin As, vitamin Ds, nifedipin, indomethacin and vitamin Ks, especially activated vitamin Ds (e.g. 1alpha-hydroxycholecalcipherol).
1329254 Oral preparations COLGATEPALMOLIVE CO 3 May 1971 [4 June 1970 27 Nov 1970] 27027/70 and 56576/70 Heading A5B Oral preparations comprise, as a non-toxic antibacterial agent an aminocyano polymeric diguanide or a mixture of such polymers having the formula wherein Y represents NH 2 (CH 2 ) 6 - or X represents -NH 2  or and n is an integer from 2 to 6, or a salt, e.g. a fluoride, chloride, nitrate, sulphate, succinate, tartrate, citrate, maleate or methosulphate, or mixture of salts of such polymer or polymers; and, as a vehicle for the antibacterial agent, a mixture of water and alcohol or a solid waterinsoluble dental polishing material. The preparations may be in the form of a dentifrice such as a toothpaste, dental cream, tooth powder or liquid dentifrice, a mouthwash or rinse, dental chewing gum, dental floss, tablet, lozenge or troche. The preparations may also contain a fluorine-providing compound such as sodium fluoride, stannous fluoride or sodium monofluorophosphate; a surface active agent, preferably an anionic surface active agent such as sodium lauryl sulphate or sodium N-lauroyl sarcosinate, or a nonionic surface active agent such as condensates of ethylene oxide with sorbitan monostearate, or condensates of ethylene oxide or propylene oxide with propylene glycol, or an amphoteric agent such as quaternized imidazole derivatives; a humectant such as glycerine, sorbitol or propylene glycol; a gelling agent such as hydroxyethyl cellulose or carboxymethyl-cellulose; an additional antibacterial agent such as 1,6-di-(p-chlorophenyl biguanidohexane); a colouring or whitening agent; a preservative such as sodium benzoate; a silicone; a chlorophyll compound; an ammoniated material such as urea and/or diammonium phosphate; a flavouring and/or sweetening material, e.g. sodium saccharin. The polishing material may be insoluble sodium metaphosphate, dicalcium phosphate (dihydrate or anhydrous), alumina, calcium carbonate, tetrasodium, pyrophosphate, silica, and/or polymethyl methacrylate.
Senile plaque blue autofluorescence was discovered around 40 years ago, however, its impact on Alzheimer's disease (AD) pathology has not been fully examined. We analyzed senile plaques with immunohistochemistry and fluorescence imaging on AD brain sections and also Aβ aggregation in vitro. In DAPI or Hoechst staining, the nuclear blue fluorescence could only be correctly assigned after subtracting the blue plaque autofluorescence. The flower-like structures wrapping dense-core blue fluorescence formed by cathepsin D staining could not be considered central-nucleated neurons with defective lysosomes since there was no nuclear staining in the plaque core when the blue autofluorescence was subtracted. Both Aβ self-oligomers and Aβ/hemoglobin heterocomplexes generated blue autofluorescence. The Aβ amyloid blue autofluorescence not only labels senile plaques but also illustrates red cell aggregation, hemolysis, cerebral amyloid angiopathy, vascular plaques, vascular adhesions, and microaneurysms. In summary, we conclude that Aβ-aggregation-generated blue autofluorescence is an excellent multi-amyloidosis marker in Alzheimer's disease.
BACKGROUND: Our objective was to investigate the predictive and diagnostic accuracy of the angiogenic proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) for preterm preeclampsia and explore the relationship between renal function and these proteins.
METHODS: We completed a blinded, prospective, longitudinal, observational study of patients with chronic kidney disease followed at a tertiary center (2018-2023). Serum samples were obtained at 3 time points along gestation (planned sampling): 12-16, 18-22, and 28-32 weeks. In addition, samples were obtained whenever preeclampsia was suspected (indicated sampling). sFlt-1 and PlGF levels remained concealed until the study ended. The primary outcome was preterm preeclampsia. The planned and indicated samples were used to estimate the predictive and diagnostic accuracy of the angiogenic proteins, respectively.
RESULTS: Of the 97 participants, 21 (21.6%) experienced preterm preeclampsia. In asymptomatic patients with chronic kidney disease, the angiogenic proteins were predictive of preterm preeclampsia only when sampled in the third trimester, in which case the sFlt-1/PlGF ratio (false positive rate of 37% for a detection rate of 80%) was more predictive than either sFlt-1 or PlGF in isolation. In patients with suspected preeclampsia, the diagnostic accuracy of the sFlt-1/PlGF ratio (false positive rate of 26% for a detection rate of 80%) was higher than that of sFlt-1 and PlGF in isolation. Diminished renal function was associated with increased levels of PlGF.
CONCLUSIONS: sFlt-1 and PlGF can effectively predict and improve the diagnostic accuracy for preterm preeclampsia among patients with chronic kidney disease. The optimal sFlt-1/PlGF ratio cutoff to rule out preeclampsia may need to be lower in patients with impaired renal function.
Fludarabine and busulfan was considered as myeloablative but reduced toxicity regimen and became as the mainstay of conditioning regimen for adult patients with acute myeloid leukemia (AML) or myelodysplasia syndrome (MDS). The disease relapse remained as major cause of treatment failure. In general, the cumulated incidence of relapse (CIR) is about 15\~20% dependent on the risk of patients undergoing allogeneic stem cell transplantation (allo-HSCT). Conditioning regimen with dual alkylating agents such as fludarabine, busulfan and thiotepa (TBF) showed decreased risk of relapse in myeloid malignancies. More recently, the investigators demonstrated that conditioning regimen with dual alkylating agents consistent of fludarabine, busulfan and melphalan could achieve a low incidence of relapse (2 year CIR \<10%). In this multiple-center randomize study, the aim is to compare the transplantation outcome in adult patients with AML/MDS undergoing allo-HSCT with conditioning regimen of Flu-Bu vs. Flu-Bu-Mel.